The necessity and quandaries of dengue vaccine development

Journal of Infectious Diseases

Volumn 203, Issue 3, 2011, Pages 299-303

  Thomas, Stephen J ^a  

^a ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; DNA VACCINE; ENDEMIC AND HYPERENDEMIC DENGUE VIRUS DNA VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS ENVELOPE PROTEIN;

CELLULAR IMMUNITY; DENGUE VIRUS; ENDEMIC AND HYPERENDEMIC DENGUE VIRUS; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MUTAGENESIS; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTECTIVE EQUIPMENT; VECTOR CONTROL; VIREMIA; VIRUS ATTENUATION; VIRUS STRAIN; VIRUS TRANSMISSION; YELLOW FEVER;

CLINICAL TRIALS AS TOPIC; COMMUNICABLE DISEASES, EMERGING; DENGUE; DENGUE VACCINES; DISEASE OUTBREAKS; HUMANS; WORLD HEALTH;

EID: 79751498009     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq060     Document Type: Note

References (99)

1. Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 2002; 10:100-3. (Pubitemid 34119347)
2. Thomas SJ, Strickman D, Vaughn DW. Dengue epidemiology: virus epidemiology, ecology, and emergence. Adv Virus Res 2003; 61:235-89. (Pubitemid 137639388)
3. Ayyub M, Khazindar AM, Lubbad EH, Barlas S, Alfi AY, Al-Ukayli S. Characteristics of dengue fever in a large public hospital, Jeddah, Saudi Arabia. J Ayub Med Coll Abbottabad 2006; 18:9-13.
4. Ahmed S, Arif F, Yahya Y, et al. Dengue fever outbreak in Karachi 2006-a study of profile and outcome of children under 15 years of age. J Pak Med Assoc 2008; 58:4-8.
5. Dorji T, Yoon IK, Holmes EC, et al. Diversity origin of dengue virus serotypes 1, 2, and 3, Bhutan. Emerg Infect Dis 2009; 15:1630-2.
6. Effler PV, Pang L, Kitsutani P, et al. Dengue fever, Hawaii, 2001-2002. Emerg Infect Dis 2005; 11:742-9.
7. Ramos MM, Mohammed H, Zielinski-Gutierrez E, et al. Epidemic dengue dengue hemorrhagic fever at the Texas-Mexico border: results of a household-based seroepidemiologic survey, December 2005. Am J Trop Med Hyg 2008; 78:364-9. (Pubitemid 351845181)
8. Dengue hemorrhagic fever-U.S.-Mexico border, 2005. Morb Mortal Wkly Rep 2007; 56:785-9.
9. From the Centers for Disease Control Prevention. Dengue fever at the US-Mexico border, 1995-1996. JAMA. 1996; 276:1464-65.
10. Rigau-Perez JG, Gubler DJ, Vorndam AV, Clark GG. Dengue surveillance-United states, 1986-1992. MMWR CDC Surveill Summ 1994; 43:7-19.
11. Morens DM, Fauci AS. Dengue and hemorrhagic fever: a potential threat to public health in the United States. JAMA 2008; 299:214-216.
12. Locally acquired Dengue-Key West, Florida, 2009-2010. Morb Mortal Wkly Rep 2010; 59:577-81.
13. Laferl H, Szell M, Bischof E, Wenisch C. Imported dengue fever in Austria 1990-2005. Travel Med Infect Dis 2006; 4:319-23.
14. Wilder-Smith A, Schwartz E. Dengue in travelers. N Engl J Med 2005; 353:924-32. (Pubitemid 41247932)
15. Travel-associated dengue infections-United States, 2001-2004. Morb Mortal Wkly Rep 2005; 54:556-58.
16. Sung V, O'Brien DP, Matchett E, Brown GV, Torresi J. Dengue Fever in travelers returning from southeast Asia. J Travel Med 2003; 10:208-13. (Pubitemid 36987923)
17. Trofa AF, DeFraites RF, Smoak BL, et al. Dengue fever in US military personnel in Haiti. JAMA 1997; 277:1546-48. (Pubitemid 27213304)
18. From the Centers for Disease Control Prevention. Dengue fever among U.S. military personnel-Haiti, September-November, 1994. JAMA. 1995; 273:14-15.
19. Dengue and dengue haemorrhagic fever. Available at: http://www.who.int/ mediacentre/ factsheets/fs117/en/. Accessed 10 October 2010 2010.
20. Luz PM, Grinsztejn B, Galvani AP. Disability adjusted life years lost to dengue in Brazil. Trop Med Int Health 2009; 14:237-46.
21. Huy R, Wichmann O, Beatty M, et al. Cost of dengue and other febrile illnesses to households in rural Cambodia: a prospective community-based case-control study. BMC Public Health 2009; 9:155.
22. Garg P, Nagpal J, Khairnar P, Seneviratne SL. Economic burden of dengue infections in India. Trans R Soc Trop Med Hyg 2008; 102:570-77.
23. Torres JR, Castro J. The health and economic impact of dengue in Latin America. Cad Saude Publica 2007; 23:S23-S31.
24. Anderson KB, Chunsuttiwat S, Nisalak A, et al. Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study. Lancet 2007; 369:1452-59. (Pubitemid 46635782)
25. Clark DV, Mammen MP Jr, Nisalak A, Puthimethee V, Endy TP. Economic impact of dengue fever/dengue hemorrhagic fever in Thailand at the family and population levels. Am J Trop Med Hyg 2005; 72:786-91. (Pubitemid 41278800)
26. Simmons JS, St John JH, Reynolds FHK. Experimental studies of dengue. Philippine J Sci 1931; 44:1-252.
27. Schlesinger RW, Gordon I, Frankel JW, Winter JW, Patterson PR, Dorrance WR. Clinical and serologic response of man to immunization with attnuated dengue and yellow fever viruses. JImmunol 1956; 77: 352-64.
28. Sabin AB, Schlesinger RW. Production of immunity to dengue with virus modified by propagation in mice. Science (New York, NY) 1945; 101:640-42.
29. Wisseman CL Jr, Sweet BH, Rosenzweig EC, Eylar OR. Attenuated living type 1 dengue vaccines. Am J Trop Med Hyg 1963; 12:620-23.
30. Halstead SB, Diwan AR, Marchette NJ, Palumbo NE, Srisukonth L. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. I. Attributes of uncloned virus at different passage levels. Am J Trop Med Hyg 1984; 33:654-65.
31. Bhamarapravati N, Yoksan S, Chayaniyayothin T, Angsubphakorn S, Bunyaratvej A. Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers. Bull World Health Organ 1987; 65:189-95. (Pubitemid 17089851)
32. Bhamarapravati N, Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine 2000; 18:44-7. (Pubitemid 30252002)
33. Sabchareon A, Lang J, Chanthavanich P, et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 2004; 23:99-109. (Pubitemid 38222779)
34. Sabchareon A, Lang J, Chanthavanich P, et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 2002; 66:264-72. (Pubitemid 34756095)
35. Sun W, Cunningham D, Wasserman SS, et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Hum Vaccin 2009; 5:33-40.
36. Sun W, Edelman R, Kanesa-Thasan N, et al. Vaccination of human volunteers with monovalent tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 2003; 69:24-31.
37. Kanesa-Thasan N, Edelman R, Tacket CO, et al. Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines. Am J Trop Med Hyg 2003; 69:17-23.
38. Innis BL, Eckels KH. Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. Am J Trop Med Hyg 2003; 69:1-4.
39. Eckels KH, Dubois DR, Putnak R, et al. Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys. Am J Trop Med Hyg 2003; 69:12-6.
40. Simasathien S, Thomas SJ, Watanaveeradej V, et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am J Trop Med Hyg 2008; 78:426-33. (Pubitemid 351845193)
41. Durbin AP, Karron RA, Sun W, et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am J Trop Med Hyg 2001; 65:405-13. (Pubitemid 33134570)
42. Blaney JE Jr, Durbin AP, Murphy BR, Whitehead SS. Targeted mutagenesis as a rational approach to dengue virus vaccine development. Curr Top Microbiol Immunol 2010; 338:145-58.
43. Wright PF, Durbin AP, Whitehead SS, et al. Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers. Am J Trop Med Hyg 2009; 81:834-41.
44. Durbin AP, McArthur JH, Marron JA, et al. rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe highly immunogenic in healthy dengue-naive adults. Hum Vaccin 2006; 2:255-60. (Pubitemid 46025657)
45. Blaney JE Jr, Durbin AP, Murphy BR, Whitehead SS. Development of a live attenuated dengue virus vaccine using reverse genetics. Viral Immunol 2006; 19:10-32.
46. Safety study of a dengue virus DNA vaccine. Available at: http://clinicaltrials.gov/ct2/show/NCT00290147?term=dengue+and+ dna&rank=+. Accessed October 12, 2010 2010.
47. Raviprakash K, Apt D, Brinkman A, et al. A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques. Virology 2006; 353:166-73. (Pubitemid 44291778)
48. Raviprakash K, Kochel TJ, Ewing D, et al. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. Vaccine 2000; 18:2426-34. (Pubitemid 30156814)
49. Raviprakash K, Porter KR, Kochel TJ, et al. Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. J Gen Virol 2000; 81:1659-67. (Pubitemid 30427070)
50. Raviprakash K, Wang D, Ewing D, et al. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. J Virol 2008 Jul; 82(14):6927-34. (Pubitemid 351977713)
51. Clements DE, Coller BA, Lieberman MM, et al. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 2010; 28:2705-15.
52. Putnak R, Coller BA, Voss G, et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 2005; 23:4442-52. (Pubitemid 40991230)
53. Study of HBV-001 D1 in healthy adults. Available at: http:// clinicaltrials.gov/ct2/show/ NCT00936429?term=hawaii+biotech& rank=2. Accessed 12 October 2010.
54. Jones T. Technology evaluation Vax-DEN, Acambis/Aventis. Curr Opin Mol Ther 2004; 6:443-50.
55. Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010; 28:632-49.
56. Guirakhoo F, Kitchener S, Morrison D, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2006; 2:60-7. (Pubitemid 43927159)
57. Guy B, Saville M, Lang J. Development of Sanofi Pasteur tetravalent dengue vaccine. Hum Vaccin 2010; 6.
58. Lang J. Recent progress on sanofi pasteur's dengue vaccine candidate. J Clin Virol 2009; 46:S20-S24.
59. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 2010; 201: 370-7.
60. Edelman R, Hombach J. "Guidelines for the clinical evaluation of dengue vaccines in endemic areas": summary of a World Health Organization technical consultation. Vaccine 2008; 26:4113-19.
61. Guy B, Barban V, Mantel N, et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 2009; 80:302-11.
62. Edelman R, Wasserman SS, Bodison SA, et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 2003; 69:48-60.
63. Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol. 2006 Oct; 80(20):10208-17. (Pubitemid 44522614)
64. Williams KL, Zompi S, Beatty PR, Harris E. A mouse model for studying dengue virus pathogenesis and immune response. Ann N Y Acad Sci 2009; 1171:E12-E23.
65. Cassetti MC, Durbin A, Harris E, Rico-Hesse R, et al. Report of an NIAID workshop on dengue animal models. Vaccine 2010; 28:4229-34.
66. Onlamoon N, Noisakran S, Hsiao HM, et al. Dengue virus-induced hemorrhage in a nonhuman primate model. Blood 2010; 115:1823-34.
67. Tan GK, Ng JK, Trasti SL, Schul W, Yip G, Alonso S. A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice. PLoS Negl Trop Dis 2010; 4:e672.
68. Chulay JD, Schneider I, Cosgriff TM, et al. Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg 1986; 35:66-8. (Pubitemid 16140838)
69. Ashburn PM, Craig CF. Experimental investigations regarding the etiology of dengue fever. J Infect Dis 1907; 4:440-75.
70. Siler JF, Hall MW, Hitchens AP. Dengue: its history, epidemilogy, mechanism of transmission, etiology, clinical manifestations, immunity, and prevention. Philippine J Sci 1926; 29:1-304.
71. Hotta S. Experimental studies on dengue. I. Isolation, identification and modification of the virus. J Infect Dis 1952; 90:1-9.
72. Innis BL, Eckels KH, Kraiselburd E, et al. Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation. J Infect Dis 1988; 158:876-80.
73. McKee KT Jr, Bancroft WH, Eckels KH, Redfield RR, Summers PL, Russell PK. Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers. Am J Trop Med Hyg 1987; 36:435-42. (Pubitemid 17057551)
74. Statler J, Mammen M, Lyons A, Sun W. Sonographic findings of healthy volunteers infected with dengue virus. J Clin Ultrasound 2008; 36:413-17.
75. Halstead SB. In vivo enhancement of dengue virus infection in Rhesus monkeys by passively transferred antibody. J Infect Dis 1979; 140:527-33.
76. Halstead SB, Porterfield JS, O'Rourke EJ. Enhancement of dengue virus infection in monocytes by flavivirus antisera. Am J Trop Med Hyg 1980; 29:638-42. (Pubitemid 10011093)
77. Kurane I, Mady BJ, Ennis FA. Antibody-dependent enhancement of dengue virus infection. Rev Med Virol 1991; 1:211-21.
78. Burke DS, Kliks S. Antibody-dependent enhancement in dengue virus infections. J Infect Dis 2006; 193:601-3 author reply 603-4.
79. Libraty DH, Acosta LP, Tallo V, et al. A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med 2009; 6:e1000171.
80. Dejnirattisai W, Jumnainsong A, Onsirisakul N, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science (New York, NY) 2010; 328:745-48.
81. Simmons CP, Dong T, Chau NV, et al. Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections. J virology 2005; 79:5665-75. (Pubitemid 40548235)
82. Rothman AL. Cellular immunology of sequential dengue virus infection and its role in disease pathogenesis. Curr Top Microbiol Immunol 2010; 338:83-98.
83. Friberg H, Burns L, Woda M, et al. Memory CD8(+) T cells from naturally acquired primary dengue virus infection are highly cross-reactive. Immunol Cell Biol 2010. Apr 27. [Epub ahead of print].
84. Mathew A, Rothman AL. Understanding the contribution of cellular immunity to dengue disease pathogenesis. Immunol Rev 2008; 225:300-13.
85. Green S, Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 2006; 19:429-36. (Pubitemid 44338101)
86. Sanchez V, Gimenez S, Tomlinson B, et al. Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3). Vaccine 2006; 24:4914-26. (Pubitemid 43782690)
87. Rabablert J, Dharakul T, Yoksan S, Bhamarapravati N. Dengue virus specific T cell responses to live attenuated monovalent dengue-2 and tetravalent dengue vaccines. Asian Pac J Allergy Immunol/ launched by Allergy Immunol Soc Thailand 2000; 18:227-35. (Pubitemid 32249032)
88. Rabablert J, Yoksan S. Attenuated D2 16681-PDK53 vaccine: defining humoral and cell-mediated immunity. Curr Pharm Des 2009; 15:1203-11.
89. Green S, Kurane I, Edelman R, et al. Dengue virus-specific human CD4+ T-lymphocyte responses in a recipient of an experimental live-attenuated dengue virus type 1 vaccine: bulk culture proliferation, clonal analysis, and precursor frequency determination. J Virol 1993; 67:5962-7. (Pubitemid 23277507)
90. Guy B. Immunogenicity of sanofi pasteur tetravalent dengue vaccine. J Clin Virol 2009; 46:S16-S19.
91. Guy B, Nougarede N, Begue S, et al. Cellmediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus- primed subjects. Vaccine 2008; 26:5712-21.
92. Rothman AL, Kanesa-thasan N, West K, Janus J, Saluzzo JF, Ennis FA. Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine. Vaccine 2001; 19:4694-99. (Pubitemid 32800752)
93. Hombach J, Cardosa MJ, Sabchareon A, Vaughn DW, Barrett AD. Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005. Vaccine 2007; 25:4130-39.
94. Vorndam V, Beltran M. Enzyme-linked immunosorbent assay-format microneutralization test for dengue viruses. Am J Trop Med Hyg 2002; 66:208-12. (Pubitemid 34755655)
95. Roehrig JT, Hombach J, Barrett AD. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 2008; 21:123-32. (Pubitemid 351873374)
96. Putnak JR, de la Barrera R, Burgess T, et al. Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies. Am J Trop Med Hyg 2008; 79:115-22. (Pubitemid 351957214)
97. Thomas SJ, Nisalak A, Anderson KB, et al. Dengue plaque reduction neutralization test (PRNT) in primary secondary dengue virus infections: how alterations in assay conditions impact performance. Am J Trop Med Hyg 2009; 81:825-33.
98. Chanthavanich P, Luxemburger C, Sirivichayakul C, et al. Short report: immune response occurrence of dengue infection in thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccine. Am J Trop Med Hyg 2006; 75:26-8. (Pubitemid 351627565)
99. Durbin et al. J Infect Dis 2011; 203:327-334 (in this issue).